Developer docs
API playgroundTry for free, no card

Search company profiles

Biopas

Full company profile

uuid000hp1a

Namestring
Biopas
Legal namestring
Biopas
Websiteurl
biopasgroup.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Biopas is a Bogota-headquartered biopharmaceutical commercialization platform that operates as a subsidiary of Swiss-based Swixx Biopharma AG. Founded in 2002, the company provides end-to-end launch and growth infrastructure for global pharmaceutical manufacturers seeking to bring innovative specialty products into Latin American markets. Its core platform integrates sales, marketing, medical affairs, market access, regulatory affairs, pharmacovigilance, supply chain, and compliance services, delivered through fully owned subsidiaries in at least eight countries (Brazil, Argentina, Colombia, Mexico, Chile, Peru, Guatemala, Costa Rica) supported by QC laboratories in Brazil and Argentina and a network of certified cold-chain 3PL partners.

The company maintains 600+ active Marketing Authorizations across the region and specializes in therapy areas where global pharma typically faces launch complexity in LATAM: CNS, immunology, dermatology, oncology, gastroenterology, and rare/orphan diseases. Its named partner roster spans major and specialty manufacturers including AstraZeneca, UCB, Lundbeck, Ipsen, Jazz Pharmaceuticals, Daiichi Sankyo, Chiesi, LEO Pharma, Merz Therapeutics, Ferring, Bial, Acorda, Mirum, Proveca, and others. Direct-to-HCP commercial engagement is supported by field sales and medical detailing teams, while a dedicated healthcare-professional portal (BiopasMed) channels scientific and product information to prescribers.

Biopas operates a 350+ employee organization led by founders Pascal Forget (Executive Regional General Manager LATAM) and Maria Fernanda Forget (COO LATAM), with a full CXO bench drawn from Pfizer, Abbott, AbbVie, Sanofi, and Biogen. The company's revenue model is contract-based: global pharma partners grant product commercialization rights for defined LATAM territories in multi-year contracts, and Biopas earns margins on sales and services. ISO 37001:2016 anti-bribery certification, alignment with EMA/FDA QC standards, and adherence to WHO/PAHO pharmacovigilance guidelines underpin the governance posture required by multinational partners.

Short descriptiontext

Biopas is a Bogota-headquartered pharmaceutical commercialization platform (subsidiary of Swixx Biopharma, Switzerland) that helps global manufacturers launch and grow innovative specialty drugs across Latin America through owned subsidiaries in eight countries, providing regulatory, medical, market access, and distribution services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBogotá, Colombia
HQ citystring
Bogotá
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical commercialization, specialty pharma distribution, pharma market access, regulatory affairs services, pharmacovigilance services
Industry4 codes
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAAAHAL
Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Commercialization Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Commercialization
TypeLicensing Royalties
Description

Biopas generates revenue by commercializing innovative pharmaceutical products from global pharmaceutical partners in the Latin American region. The company provides end-to-end services including sales, marketing, medical affairs, market access, regulatory, and distribution, earning margins on product commercialization through established partnerships with major pharmaceutical companies.

swixxbiopharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure, Others
Pricing details1 tier
1B2B pharmaceutical partnership model
ModelOtherBilling cadenceMulti-year contract
Notes

Contract-based pricing negotiated with pharmaceutical partners for product commercialization rights in specific Latin American territories

swixxbiopharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BiopasMed
Description

Exclusive portal for healthcare professionals in Latin America

swixxbiopharma.com
Core offering1 text field

Biopas commercializes innovative pharmaceutical products from global pharmaceutical partners across Latin America through fully owned subsidiaries. It provides end-to-end pharmaceutical commercialization services including sales, marketing, medical affairs, market access, regulatory and quality management, pharmacovigilance, supply chain distribution, and patient support programs across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drug therapy areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Maintains 600+ active Marketing Authorizations across Latin America
+1 more record
Product overview1 text field

Biopas, a Swixx Biopharma company, operates as a comprehensive pharmaceutical commercialization platform in Latin America. The company provides a unified portfolio of integrated services including Marketing, Medical Affairs, Market Access, Patient Support Programs, Compliance, Regulatory & Quality, Supply Chain, and Pharmacovigilance services. Operating across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drugs with over 600 active Marketing Authorizations and 350+ employees, Biopas serves as a turnkey solution for launching and growing pharmaceutical products in the region through fully owned subsidiaries.

Product and service1 record
1Pharmaceutical Commercialization Platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership23 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership for commercializing innovative products in Latin America. Biopas provides commercialization platform while Acorda supplies specialty pharmaceutical products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major global pharmaceutical company partnership for commercializing products across LATAM markets including CNS, immunology, and other therapy areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Portuguese pharmaceutical company partnership for commercializing innovative medicines in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Italian pharmaceutical company partnership for product commercialization in LATAM markets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

South Korean pharmaceutical company partnership for commercializing products in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Japanese pharmaceutical company partnership for commercializing innovative pharmaceutical products across LATAM.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Specialty pharma partnership for reproductive medicine and other specialized therapeutic areas in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

French pharmaceutical company partnership for commercializing specialty medicines in LATAM markets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Irish pharmaceutical company partnership for commercializing innovative therapies including psychiatry and neurology products in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Danish pharmaceutical company specializing in dermatology, partnership for skin disease treatments in LATAM.

11LFB
Strategic tierCoreTypeStrategic or Co-development Partner
Description

French biopharmaceutical company partnership for plasma-derived medicines commercialization in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Danish pharmaceutical company specializing in CNS disorders, partnership for neuroscience products in LATAM.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

German pharmaceutical company partnership for commercializing neurology and aesthetic medicine products in Latin America.

14UCB
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Belgian pharmaceutical company partnership for immunology and neurology products commercialization in LATAM.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

German pharmaceutical company partnership for commercializing established branded medicines in Latin America.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical devices and pharmaceutical products partnership for Latin American markets.

17Dr. Pfleger
Strategic tierMinorTypeStrategic or Co-development Partner
Description

German pharmaceutical company partnership for product commercialization in LATAM.

swixxbiopharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

French pharmaceutical company partnership for gastroenterology and other specialty products in Latin America.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

German pharmaceutical company partnership for commercializing medicines in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Specialty pharmaceutical company partnership for rare disease medicines in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Israeli pharmaceutical company specializing in CNS disorders, partnership for neuroscience products in LATAM.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Swiss pharmaceutical company partnership for commercializing established medicines across LATAM.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

UK specialty pharmaceutical company partnership for pediatric medicines in Latin America.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Latin American specialty pharmaceutical commercialization company that partners with global pharma to bring innovative medicines to LATAM markets. Most directly comparable peer to Biopas by business model and regional focus.

TypeDirect peer
Description

Latin American pharmaceutical group with a broad specialty and branded generics portfolio distributed across multiple LATAM countries. Comparable to Biopas as a multi-country LATAM pharma operator with partner-driven commercialization.

TypeBroad incumbent
Description

Large Mexican/LATAM pharmaceutical company commercializing branded pharmaceutical and personal-care products across Latin America. Broader incumbent with overlapping LATAM commercialization capabilities.

4Eurofarma
TypeBroad incumbent
Description

Brazilian-headquartered multinational pharmaceutical company with manufacturing and commercialization across Latin America. Comparable as a major LATAM-headquartered pharma operator serving similar geographic footprint.

5Grupo Insud (Insud Pharma)
TypeDirect peer
Description

Spanish-Argentine pharmaceutical group operating across branded, OTC, and specialty medicine commercialization in LATAM and Europe. Comparable partner-driven, multi-country pharmaceutical commercialization model.

TypeDirect peer
Description

Global specialty pharmaceutical company with strong women's health and specialty care presence across LATAM. Operates a similar partner-led commercialization model in Latin American markets.

TypeRegional player
Description

Brazilian pharmaceutical manufacturer and commercializer across multiple therapeutic categories. Comparable primarily within the Brazilian pharma market that Biopas treats as a core country.

TypeRegional player
Description

Brazilian pharmaceutical company commercializing branded specialty medicines in Brazil and select LATAM markets. Comparable to Biopas within the Brazilian specialty pharma commercialization segment.

9Asofarma
TypeRegional player
Description

Mexican pharmaceutical group with branded generics and specialty pharma portfolios across Mexico and Central America. Comparable LATAM specialty pharmaceutical operator.

TypeBroad incumbent
Description

Global biopharmaceutical company operating its own LATAM commercial organization across the same countries Biopas serves — both as a current Biopas partner and as a benchmark for what an in-house alternative could look like.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biopas

Pharmaceutical Commercialization Servicesbiopasgroup.com

Biopas is a Bogota-headquartered pharmaceutical commercialization platform (subsidiary of Swixx Biopharma, Switzerland) that helps global manufacturers launch and grow innovative specialty drugs across Latin America through owned subsidiaries in eight countries, providing regulatory, medical, market access, and distribution services.

What Biopas does

Biopas is a Bogota-headquartered biopharmaceutical commercialization platform that operates as a subsidiary of Swiss-based Swixx Biopharma AG. Founded in 2002, the company provides end-to-end launch and growth infrastructure for global pharmaceutical manufacturers seeking to bring innovative specialty products into Latin American markets. Its core platform integrates sales, marketing, medical affairs, market access, regulatory affairs, pharmacovigilance, supply chain, and compliance services, delivered through fully owned subsidiaries in at least eight countries (Brazil, Argentina, Colombia, Mexico, Chile, Peru, Guatemala, Costa Rica) supported by QC laboratories in Brazil and Argentina and a network of certified cold-chain 3PL partners.

The company maintains 600+ active Marketing Authorizations across the region and specializes in therapy areas where global pharma typically faces launch complexity in LATAM: CNS, immunology, dermatology, oncology, gastroenterology, and rare/orphan diseases. Its named partner roster spans major and specialty manufacturers including AstraZeneca, UCB, Lundbeck, Ipsen, Jazz Pharmaceuticals, Daiichi Sankyo, Chiesi, LEO Pharma, Merz Therapeutics, Ferring, Bial, Acorda, Mirum, Proveca, and others. Direct-to-HCP commercial engagement is supported by field sales and medical detailing teams, while a dedicated healthcare-professional portal (BiopasMed) channels scientific and product information to prescribers.

Biopas operates a 350+ employee organization led by founders Pascal Forget (Executive Regional General Manager LATAM) and Maria Fernanda Forget (COO LATAM), with a full CXO bench drawn from Pfizer, Abbott, AbbVie, Sanofi, and Biogen. The company's revenue model is contract-based: global pharma partners grant product commercialization rights for defined LATAM territories in multi-year contracts, and Biopas earns margins on sales and services. ISO 37001:2016 anti-bribery certification, alignment with EMA/FDA QC standards, and adherence to WHO/PAHO pharmacovigilance guidelines underpin the governance posture required by multinational partners.

Biopas firmographics

Firmographics
Name
Biopas
Legal name
Biopas
Website
https://biopasgroup.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Biopas is a Bogota-headquartered pharmaceutical commercialization platform (subsidiary of Swixx Biopharma, Switzerland) that helps global manufacturers launch and grow innovative specialty drugs across Latin America through owned subsidiaries in eight countries, providing regulatory, medical, market access, and distribution services.
Ownership category
akta.pro rank

Biopas industry classification

Industry
Product category
Pharmaceutical Commercialization Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAAAHAL
Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Pharmaceutical commercialization
  • Specialty pharma distribution
  • Pharma market access
  • Regulatory affairs services
  • Pharmacovigilance services

Where Biopas is headquartered

Location

Headquarters

HQ city
Bogotá
HQ country
Colombia
HQ region
Latin America

Offices10 records

Markets served

Biopas business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure, Others

Revenue model

  1. Pharmaceutical Product Commercialization: Biopas generates revenue by commercializing innovative pharmaceutical products from global pharmaceutical partners in the Latin American region. The company provides end-to-end services including sales, marketing, medical affairs, market access, regulatory, and distribution, earning margins on product commercialization through established partnerships with major pharmaceutical companies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B pharmaceutical partnership model

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Biopas product offering

Product offering

Core offering

Biopas commercializes innovative pharmaceutical products from global pharmaceutical partners across Latin America through fully owned subsidiaries. It provides end-to-end pharmaceutical commercialization services including sales, marketing, medical affairs, market access, regulatory and quality management, pharmacovigilance, supply chain distribution, and patient support programs across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drug therapy areas.

Product overview

Biopas, a Swixx Biopharma company, operates as a comprehensive pharmaceutical commercialization platform in Latin America. The company provides a unified portfolio of integrated services including Marketing, Medical Affairs, Market Access, Patient Support Programs, Compliance, Regulatory & Quality, Supply Chain, and Pharmacovigilance services. Operating across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drugs with over 600 active Marketing Authorizations and 350+ employees, Biopas serves as a turnkey solution for launching and growing pharmaceutical products in the region through fully owned subsidiaries.

Differentiator

Problem solved

Functional benefit

Brands

  • BiopasMed: Exclusive portal for healthcare professionals in Latin America

Products and services

  • Pharmaceutical Commercialization Platform

Quantifiable outcome

  • Maintains 600+ active Marketing Authorizations across Latin America
  • +1 more outcomes

Companies that use Biopas

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Biopas technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Biopas partnerships and signals

Strategic signal

Partnerships

23 partnerships are on record, tiered core and minor.

  • Acorda TherapeuticscoreStrategic or Co-development PartnerPharmaceutical partnership for commercializing innovative products in Latin America. Biopas provides commercialization platform while Acorda supplies specialty pharmaceutical products.
  • AstraZenecacoreStrategic or Co-development PartnerMajor global pharmaceutical company partnership for commercializing products across LATAM markets including CNS, immunology, and other therapy areas.
  • BialcoreStrategic or Co-development PartnerPortuguese pharmaceutical company partnership for commercializing innovative medicines in Latin America.
  • ChiesicoreStrategic or Co-development PartnerItalian pharmaceutical company partnership for product commercialization in LATAM markets.
  • Daewoong PharmaceuticalcoreStrategic or Co-development PartnerSouth Korean pharmaceutical company partnership for commercializing products in Latin America.
  • Daiichi SankyocoreStrategic or Co-development PartnerJapanese pharmaceutical company partnership for commercializing innovative pharmaceutical products across LATAM.
  • Ferring PharmaceuticalscoreStrategic or Co-development PartnerSpecialty pharma partnership for reproductive medicine and other specialized therapeutic areas in Latin America.
  • IpsencoreStrategic or Co-development PartnerFrench pharmaceutical company partnership for commercializing specialty medicines in LATAM markets.
  • Jazz PharmaceuticalscoreStrategic or Co-development PartnerIrish pharmaceutical company partnership for commercializing innovative therapies including psychiatry and neurology products in Latin America.
  • LEO PharmacoreStrategic or Co-development PartnerDanish pharmaceutical company specializing in dermatology, partnership for skin disease treatments in LATAM.
  • LFBcoreStrategic or Co-development PartnerFrench biopharmaceutical company partnership for plasma-derived medicines commercialization in Latin America.
  • LundbeckcoreStrategic or Co-development PartnerDanish pharmaceutical company specializing in CNS disorders, partnership for neuroscience products in LATAM.
  • Merz TherapeuticscoreStrategic or Co-development PartnerGerman pharmaceutical company partnership for commercializing neurology and aesthetic medicine products in Latin America.
  • UCBcoreStrategic or Co-development PartnerBelgian pharmaceutical company partnership for immunology and neurology products commercialization in LATAM.
  • CheplapharmminorStrategic or Co-development PartnerGerman pharmaceutical company partnership for commercializing established branded medicines in Latin America.
  • CaromedminorStrategic or Co-development PartnerMedical devices and pharmaceutical products partnership for Latin American markets.
  • Dr. PflegerminorStrategic or Co-development PartnerGerman pharmaceutical company partnership for product commercialization in LATAM.
  • Mayoly SpindlerminorStrategic or Co-development PartnerFrench pharmaceutical company partnership for gastroenterology and other specialty products in Latin America.
  • MediceminorStrategic or Co-development PartnerGerman pharmaceutical company partnership for commercializing medicines in Latin America.
  • Mirum PharmaceuticalscoreStrategic or Co-development PartnerSpecialty pharmaceutical company partnership for rare disease medicines in Latin America.
  • Neurim PharmaceuticalscoreStrategic or Co-development PartnerIsraeli pharmaceutical company specializing in CNS disorders, partnership for neuroscience products in LATAM.
  • PharmanoviaminorStrategic or Co-development PartnerSwiss pharmaceutical company partnership for commercializing established medicines across LATAM.
  • Proveca PharmaminorStrategic or Co-development PartnerUK specialty pharmaceutical company partnership for pediatric medicines in Latin America.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Biopas competitors and assessment

Company assessment

Direct peers

  • Adium Pharma: Latin American specialty pharmaceutical commercialization company that partners with global pharma to bring innovative medicines to LATAM markets. Most directly comparable peer to Biopas by business model and regional focus.
  • Megalabs: Latin American pharmaceutical group with a broad specialty and branded generics portfolio distributed across multiple LATAM countries. Comparable to Biopas as a multi-country LATAM pharma operator with partner-driven commercialization.
  • Grupo Insud (Insud Pharma): Spanish-Argentine pharmaceutical group operating across branded, OTC, and specialty medicine commercialization in LATAM and Europe. Comparable partner-driven, multi-country pharmaceutical commercialization model.
  • Exeltis: Global specialty pharmaceutical company with strong women's health and specialty care presence across LATAM. Operates a similar partner-led commercialization model in Latin American markets.

Broad incumbents

  • Genomma Lab: Large Mexican/LATAM pharmaceutical company commercializing branded pharmaceutical and personal-care products across Latin America. Broader incumbent with overlapping LATAM commercialization capabilities.
  • Eurofarma: Brazilian-headquartered multinational pharmaceutical company with manufacturing and commercialization across Latin America. Comparable as a major LATAM-headquartered pharma operator serving similar geographic footprint.
  • AstraZeneca LATAM: Global biopharmaceutical company operating its own LATAM commercial organization across the same countries Biopas serves — both as a current Biopas partner and as a benchmark for what an in-house alternative could look like.

Regional players

  • Cristália: Brazilian pharmaceutical manufacturer and commercializer across multiple therapeutic categories. Comparable primarily within the Brazilian pharma market that Biopas treats as a core country.
  • Biolab Sanus: Brazilian pharmaceutical company commercializing branded specialty medicines in Brazil and select LATAM markets. Comparable to Biopas within the Brazilian specialty pharma commercialization segment.
  • Asofarma: Mexican pharmaceutical group with branded generics and specialty pharma portfolios across Mexico and Central America. Comparable LATAM specialty pharmaceutical operator.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Biopas social profiles

Digital presence

Biopas compliance and trust

Trust signal

Compliance1 record

Biopas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biopas leadership team

Management profile

Number of profiles

Profiles6 records

Biopas funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biopas M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopas

What does Biopas do?

Biopas commercializes innovative pharmaceutical products from global pharmaceutical partners across Latin America through fully owned subsidiaries. It provides end-to-end pharmaceutical commercialization services including sales, marketing, medical affairs, market access, regulatory and quality management, pharmacovigilance, supply chain distribution, and patient support programs across CNS, immunology, dermatology, oncology, gastroenterology, and orphan drug therapy areas.

Is Biopas a public or private company?

Biopas is a private company. It is classified as corporate owned and is currently operating.

When was Biopas founded?

Biopas was founded in 2002. It employs 101 to 250 people.

Where is Biopas based?

Biopas is headquartered in Bogotá, Colombia, in the Latin America region.

How does Biopas make money?

One revenue line is on record: pharmaceutical Product Commercialization.

Who are Biopas's main competitors?

Direct peers on record are Adium Pharma, Megalabs, Grupo Insud (Insud Pharma) and Exeltis. Broad incumbents are Genomma Lab, Eurofarma and AstraZeneca LATAM. Regional players are Cristália, Biolab Sanus and Asofarma.

Does Biopas have an API?

No public API is recorded for Biopas.

What industry is Biopas in?

Biopas's product category is Pharmaceutical Commercialization Services. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in BrazilANVISA granted marketing authorization for acoramidis (BEYONTTRA) to treat ATTR-CM in Brazil, based on Phase 3 ATTRibute-CM data. The study showed a 42% reduction in composite ACM and recurrent CVH events at Month 30. Commercialization with Biopas is expected in the second half of 2026.PR NewswireBiopas : Premier fournisseur de produits pharmaceutiques spécialisés ciblant l'Amérique latineBIOPAS announced the full launch of its Brazilian operations with exclusive distribution of RIVOTRIL® starting in November 2021, expanding its strategic collaboration with CHEPLAPHARM ARZNEIMITTEL GmbH in Brazil. The initiative strengthens BIOPAS's platform as an exclusive specialized pharmaceutical company covering the entire Latin American region, positioning the company as a preferred partner for global pharmaceutical firms seeking market access in the region. BIOPAS offers partners reduced complexity, management disruptions, and time costs associated with country-specific transactions through its regional platform.PR NewswireBiopas: Führender Lösungsanbieter für Spezialpharmazeutikunternehmen, die nach Lateinamerika expandieren wollenBIOPAS, a Latin American biopharmaceutical company specializing in specialty medicines, announced the launch of its Brazilian operations in November 2021, beginning with the exclusive distribution of RIVOTRIL® under an expanded strategic partnership with CHEPLAPHARM ARZNEIMITTEL GmbH. The move strengthens BIOPAS's position as an exclusive one-stop-shop provider for specialty medications across the entire Latin American region. The company positions itself as a preferred partner for international pharma firms seeking market entry and growth in Latin America while expanding patient access to innovative treatments.PR NewswireBiopas: Leading solution provider for specialty pharmaceuticals targeting Latin AmericaBIOPAS announced the full launch of its Brazilian operations, starting exclusive distribution of RIVOTRIL in November. The move expands its collaboration with CHEPLAPHARM ARZNEIMITTEL GmbH and strengthens its platform as a one-stop shop for specialty pharmaceuticals across Latin America.PR NewswireBiopas: Leading solution provider for specialty pharmaceuticals targeting Latin AmericaBIOPAS announced the full launch of its Brazilian operations with exclusive distribution of RIVOTRIL® beginning in November 2021, expanding its existing strategic collaboration with Cheplapharm Arzneimittel GmbH into the Brazilian territory. The company positioned this move as transformational, strengthening its role as a specialty care pharmaceutical company covering all of Latin America. BIOPAS provides market access solutions for global pharma companies seeking to commercialize innovative treatments in the region, operating in therapeutic areas including CNS, Immunology, Dermatology, Oncology, and Orphan Drugs.PR NewswireBiopas: proveedor líder de soluciones para productos farmacéuticos especializados apunta a América LatinaBIOPAS, a Latin American biopharmaceutical company focused on specialty pharmaceutical licensing and commercialization, announced the full launch of its operations in Brazil with exclusive distribution of RIVOTRIL® starting November 2021. This expansion marks a significant strengthening of their existing strategic collaboration with German partner CHEPLAPHARM ARZNEIMITTEL GmbH in the Brazilian territory. The company positions itself as a preferred partner for global pharmaceutical companies seeking market access and patient reach across Latin America.PR NewswireBiopas: Proveedor líder de soluciones para especialidades farmacéuticas dirigidas a LatinoaméricaBIOPAS, a leading Latin American biopharmaceutical company focused on licensing and commercializing specialized pharmaceutical products, announced the full launch of its operations in Brazil starting November, with exclusive distribution of RIVOTRIL® through an expanded strategic collaboration with CHEPLAPHARM ARZNEIMITTEL GmbH. The company positions itself as a differentiated regional platform providing market access, sales, marketing, and medical support services to global pharmaceutical partners seeking to reach patients across Latin America. This expansion reinforces BIOPAS's presence as a specialized pharmaceutical company covering the entire Latin American region, with leadership positions in CNS, Immunology, Dermatology, Oncology, and Orphan Drugs.PR NewswireBIOPAS: Líder em soluções para produtos farmacêuticos especializados na América LatinaBIOPAS, a leading Latin American biopharmaceutical company focused on licensing and commercializing specialized medications, announced the start of its operations in Brazil with exclusive distribution of RIVOTRIL® beginning in November 2021. The expansion strengthens BIOPAS's strategic partnership with CHEPLAPHARM ARZNEIMITTEL GmbH, making the company the sole complete specialty pharmaceutical care provider covering the entire Latin American region.